Suchergebnisse - "Collongues, Nicolas"

PubPharm (8)

1

Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab

enthalten in: Journal of neurology | 2022

von Demuth, S. | Bogdan, T. | Kremer, L. | +4

2

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis : an observational study

enthalten in: Journal of neurology | 2022

von Bigaut, K. | Kremer, L. | Fabacher, T. | +7

3

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders

enthalten in: Neurology(R) neuroimmunology & neuroinflammation | 2022

von Ringelstein, M. | Ayzenberg, I. | Lindenblatt, G. | +47

4

Ocrelizumab for the treatment of multiple sclerosis

enthalten in: Expert review of neurotherapeutics | 2019

von Bigaut, K. | De Seze, J. | Collongues, N.

5

Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders : Current Management and Future Options

enthalten in: Drugs | 2019

von Collongues, N. | Ayme-Dietrich, E. | Monassier, L. | +1

6

Switching from natalizumab to fingolimod in multiple sclerosis : a French prospective study

enthalten in: JAMA neurology | 2014

von Cohen, M. | Maillart, E. | Tourbah, A. | +59

CommentIn: Nat Rev Neurol. 2014 Jun;10(6):311-3. - PMID 24840971

7

Reduction of the washout time between natalizumab and fingolimod

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2013

von de Seze, J. | Ongagna, J. | Collongues, N. | +7

8

Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy

enthalten in: Journal of neurology | 2012

von Outteryck, O. | Ongagna, J. | Duhamel, A. | +9

1
[1]